PTGDR2 and asthma: Synthesized to inhibit GPR44 to reduce symptoms of asthma, the compounds were each subjected to a cAMP hGPR44 fluorescence resonance energy transfer (FRET) assay in vitro, and those with promising results were further subjected to pharmacokinetic characterization.